Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Aminoverse logo — We solve enzyme challenges. As your Enzyme CRO & Development...

Aminoverse

We solve enzyme challenges. As your Enzyme CRO & Development partner and with innovative enzyme products.

Founded 2020 The Netherlands The Netherlands 26 employees AI, Biotechnology +3

General Information

Company Name Aminoverse
Founded Year 2020
Location The Netherlands The Netherlands
Employees 26
Industries AI, Biotechnology, Life Sciences +2
Business Model B2B, E Commerce
Revenue Model Project Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Aminoverse. To contact Aminoverse, visit aminoverse.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aminoverse compare?

A PDF of Aminoverse and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aminoverse soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Sep 24, 2026

Aminoverse hosted the US session of their Exclusive Webinar: All About Biocatalysis on October 20, 2026.

Program Acceptance Sep 16, 2026

Aminoverse's lab-validated platform has been selected for the BIONetZero project, aiming to accelerate its industrial-scale implementation.

Product Launch Sep 16, 2026

Aminoverse has developed a selective, position-specific enzymatic process using novel ketoglutarate-dependent oxygenases for the production of δ-decalactone.

Get alerts when Aminoverse shows new signals

About Aminoverse

Aminoverse, founded in 2020, is a biotechnology firm based in The Netherlands that specializes in enzyme challenges, positioning itself as a strategic partner in enzyme CRO (Contract Research Organization) and development. Supported by cutting-edge enzyme wet lab research and proprietary AI technologies such as EnzyNAV AI, EnzyMAP AI, and EnzyREC AI, Aminoverse offers a comprehensive range of services from enzyme discovery to evolution.

Its unique product offerings include the world's largest collection of unspecific peroxygenases and the first keto-glutarate-dependent oxygenase panel, aimed at accelerating biocatalytic and metabolic innovations. In addition, its Phosfinity kit series uniquely enables precise polyphosphate chain length analysis. While Aminoverse has not yet reported any investment rounds, its innovative approach blends AI and biotechnology to address complex enzyme-related challenges, presenting substantial growth potential in multiple industries.

Business keywords: Enzyme Challenges, CRO Partner, Enzyme R&D, AI Integration, Enzyme Discovery, Biocatalysis, PolyPhosphate Analysis, Enzyme Engineering, Data-Directed Evolution, Computational Biology, In Silico Design, Molecular Biology, Biophysical Simulations, Enzyme Production, Quality Control

Services & Products

Enzyme Discovery
Enzyme Profiling
Enzyme Engineering
AI-Powered Enzyme Research
Enzyme Production

Target Customers

Biotech Startups Pharmaceutical Companies Agrochemical Industries Fragrance Manufacturers Academic Researchers

No funding data available for Aminoverse yet.

Aminoverse Alternatives & Competitors

View All Alternatives
Aminoverse vs
Biomatter
Biomatter Lithuania

Creating proteins with Intelligent Architecture™ for health and sustainable manufacturing

Seed
27 employees
Biopharma, Biotechnology
Aminoverse vs
DeepLife
DeepLife France

AI for digital twin of cells

Series A
31 employees
AI, Biotechnology
Aminoverse vs
SARomics Biostructures AB
SARomics Biostructures AB Sweden

Protein Crystallography & Integrated Drug Discovery: Fragment Screening & Fragment-Based Drug Design...

Venture round
31 employees
Biotechnology, Health Care
View all alternatives

FAQ About Aminoverse

We solve enzyme challenges. As your Enzyme CRO & Development partner and with innovative enzyme products.
Aminoverse was founded in 2020.
Aminoverse is headquartered in The Netherlands.
Aminoverse operates in AI, Biotechnology, Life Sciences, Manufacturing and Machine Learning. Its work centres on Enzyme Challenges, CRO Partner, Enzyme R&D and AI Integration. Its customers include Biotech Startups, Pharmaceutical Companies and Agrochemical Industries.
Aminoverse has a B2B and E Commerce business model. Its revenue comes from Project Based and Product Sales.
Aminoverse has approximately 26 employees.
Aminoverse offers: Enzyme Discovery, Enzyme Profiling, Enzyme Engineering, AI-Powered Enzyme Research, Enzyme Production.
Top alternatives and competitors to Aminoverse include Biomatter, DeepLife, SARomics Biostructures AB, Multiomic Health, MLtwist. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aminoverse and Biomatter are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aminoverse, https://bouncewatch.com/company/aminoverse, updated 24 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes